Annovis Bio, Inc. has reported the departure of Mark Guerin, effective March 23, 2026. Guerin served as the Chief Financial Officer of the company. The company stated that his departure did not arise from any disagreements regarding the company's operations, policies, or practices. Following his exit, Maria Maccecchini, the current Chief Executive Officer, is expected to take on the role of Acting Chief Financial Officer until a suitable replacement is found. This leadership change may lead to a period of adjustment within the company's financial management, which could impact investor confidence and operational execution in the short term. The company is actively seeking a new CFO to ensure continuity in its financial strategies and operations. The announcement was made in a Form 8-K filing with the SEC, which is a standard procedure for reporting significant events that shareholders should be aware of. The filing also included standard disclosures regarding the company's financial status and operational updates, but no immediate financial implications were noted. Investors will be watching closely to see how this leadership transition affects the company's strategic outlook and operational execution moving forward.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.